Insulin degludec: pharmacokinetics in patients with renal impairment.

ABSTRACT:

Background

Insulin degludec is a new-generation basal insulin with an ultra-long duration of action. We evaluated the pharmacokinetic properties of insulin degludec in subjects with normal renal function; mild, moderate or severe renal impairment; or end-stage renal disease (ESRD) undergoing hemodialysis.

Methods

Thirty subjects (n = 6 per group) received a single subcutaneous dose of 0.4 U/kg insulin degludec. Blood samples up to 120 h post-dose and fractionated urine samples were collected.

Results

The ultra-long pharmacokinetic properties of insulin degludec were preserved in subjects with renal impairment, with no statistically significant differences in absorption or clearance, compared with subjects with normal renal function. In subjects with ESRD, pharmacokine

SUBMITTER: Kiss I 

PROVIDER: S-EPMC3899495 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature